No data to show
OTCM
NDTP
Market cap187mUSD
Oct 08, Last price
1.28USD
1D
-15.83%
1Q
2,150.00%
Jan 2017
1,169,900.00%
IPO
112.73%
Name
NDT Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
250.51%
Rev. gr., 5y
-42.26%
Revenues
0k
Net income
-17k
L-78.88%
CFO
-18k
Profile
NDT Pharmaceuticals Inc., a biotechnology company, focuses on developing various therapies for severe neurological disorders associated with traumatic brain Injury. The company is based in Vienna, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | (168) | ||||||||
Tax Rate | |||||||||
NOPAT | 168 | ||||||||
Net income | (17) -78.88% | (79) | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (143) | ||||||||
| Cash flow | |||||||||
Cash from operating activities | (18) | ||||||||
CAPEX | 3 | ||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 18 | ||||||||
FCF | (41) | 209 | |||||||
| Balance | |||||||||
Cash | 647 | ||||||||
Long term investments | 142 | ||||||||
Excess cash | 143 | ||||||||
Stockholders' equity | (91) | ||||||||
Invested Capital | 192 | ||||||||
ROIC | 87.46% | ||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 160,004 | 160,004 | |||||||
Price | 0.05 -13.47% | 0.06 | |||||||
Market cap | 8,480 -13.47% | 9,800 | |||||||
EV | 8,480 | 9,657 | |||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||